Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Finished Goods (2017 - 2025)

Historic Finished Goods for Adma Biologics (ADMA) over the last 9 years, with Q3 2025 value amounting to $64.3 million.

  • Adma Biologics' Finished Goods rose 201.99% to $64.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $64.3 million, marking a year-over-year increase of 201.99%. This contributed to the annual value of $48.1 million for FY2024, which is 3153.54% down from last year.
  • As of Q3 2025, Adma Biologics' Finished Goods stood at $64.3 million, which was up 201.99% from $47.9 million recorded in Q2 2025.
  • Over the past 5 years, Adma Biologics' Finished Goods peaked at $70.3 million during Q4 2023, and registered a low of $17.5 million during Q2 2021.
  • Its 5-year average for Finished Goods is $51.5 million, with a median of $53.7 million in 2023.
  • Its Finished Goods has fluctuated over the past 5 years, first surged by 25715.55% in 2022, then tumbled by 3247.38% in 2025.
  • Over the past 5 years, Adma Biologics' Finished Goods (Quarter) stood at $29.0 million in 2021, then soared by 101.6% to $58.5 million in 2022, then rose by 20.22% to $70.3 million in 2023, then tumbled by 31.54% to $48.1 million in 2024, then soared by 33.72% to $64.3 million in 2025.
  • Its last three reported values are $64.3 million in Q3 2025, $47.9 million for Q2 2025, and $46.6 million during Q1 2025.